Annals of Gastroenterology最新文献

{"title":"Authors' reply.","authors":"Sheza Malik, Ese Uwagbale, Olayemi A Adeniranc, Arshia Sethi, Raseen Tariq","doi":"10.20524/aog.2025.0986","DOIUrl":"10.20524/aog.2025.0986","url":null,"abstract":"","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 5","pages":"577-578"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The therapeutic benefits of epigallocatechin gallate in rats with experimentally induced ulcerative colitis are achieved by influencing inflammation and apoptosis.","authors":"Abdulrhman M Al-Qarni, Abdulrhman A Eid, Abdulmajeed M Albalawi, Naif S Albalawi, Mohammed A F Elewa, Khalid S Hashem, Mohammed M H Al-Gayyar","doi":"10.20524/aog.2025.0985","DOIUrl":"10.20524/aog.2025.0985","url":null,"abstract":"<p><strong>Background: </strong>The potential therapeutic effects of epigallocatechin gallate (EGCG), a compound found in green tea with antioxidant and anti-inflammatory properties, on ulcerative colitis (UC) rats is a significant area of research. This study aimed to investigate the impact of EGCG on inflammation and apoptotic pathways in UC rats.</p><p><strong>Methods: </strong>The study involved inducing UC in rats by administering 2 mL of 4% acetic acid. The UC rats were then treated with 20 mg/kg of EGCG. Colon samples were collected to evaluate gene and protein expression of various factors, including nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), tumor necrosis factor alpha (TNF-α), sphingosine kinase 1 (SphK1), macrophage inflammatory protein 1-alpha (MIP-1α), B-cell lymphoma 2 (BCL2), and BCL2 associated X (BAX), as well as the activities of caspase-3/8/9. Additionally, colon sections were stained with Masson trichrome to investigate tissue fibrosis.</p><p><strong>Results: </strong>Microscopic examination of rat colonic sections stained with Masson trichrome revealed severe damage to the intestinal glands, marked by widespread hemorrhage and extensive fibrosis. Treatment with EGCG reduced the severity of the damage. Additionally, EGCG decreased the expression of several proinflammatory markers, such as NFκB and TNF-α, as well as SphK1, MIP-1α and BAX, reduced caspase-3/8/9 activity, and increased the expression of BCL2.</p><p><strong>Conclusions: </strong>The protective effects of EGCG against UC experimentally induced in rats are achieved by reducing the expression of inflammatory markers such as NFκB, TNF-α and MIP-1α, inhibiting apoptosis by decreasing the expression of BAX and caspases, and increasing the expression of BCL2.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 5","pages":"526-536"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tertiary referral for double balloon enteroscopy in small bowel Crohn's disease: a retrospective assessment of diagnostic impact.","authors":"Daniela Fluxa, Hasan Saleh, Christian Karime, Jing Wang, Bhaumik Brahmbhatt, Frank J Lukens, Mark Stark, Michael F Picco, Jami A Kinnucan, Jana G Hashash, Francis A Farraye","doi":"10.20524/aog.2025.0995","DOIUrl":"10.20524/aog.2025.0995","url":null,"abstract":"<p><strong>Background: </strong>Diagnosing isolated small bowel Crohn's disease (CD) can be challenging, as symptoms, imaging, and capsule endoscopy (CE) can mimic other diseases. Double balloon enteroscopy (DBE) directly evaluates the small bowel. We describe the impact of tertiary referral for DBE in patients with known or suspected small bowel CD.</p><p><strong>Methods: </strong>We carried out a retrospective review of a single tertiary-center DBE database from February 2009 to May 2013. Patients referred for DBE for known or suspected small bowel CD, based on CE, imaging and/or symptoms were included. The primary outcome was the change in diagnosis and/or management after referral for DBE. A descriptive statistical analysis was performed.</p><p><strong>Results: </strong>A total of 108 patients were included, 10 with established CD and 98 with suspected/rule-out CD. DBE changed management in 8/10 patients with known CD. In patients with suspected CD, the diagnosis was confirmed in 39/98 (40%), and management was changed in 32 of those 39 (82%). An alternative diagnosis was made or CD was ruled out in 59/98 (60%) patients with suspected CD. Prior to DBE, starting CD therapy was recommended in 24/98 (25%) patients, but DBE confirmed CD in only 15 of those 24 (63%).</p><p><strong>Conclusions: </strong>Tertiary referral for DBE in suspected CD confined to the small bowel is valuable for investigating the findings from noninvasive testing, such as CE or imaging. DBE can guide CD management and establish accurate diagnoses. Physicians should consider DBE when the diagnosis of isolated small bowel CD is not confirmed by histology.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 5","pages":"505-510"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bezlotoxumab for the prevention of recurrent <i>Clostridioides difficile</i> infection for patients with cancer.","authors":"Jaime A Peña, Cyril B Mazhuvanchery, Maria Julia Moura Nascimento Santos, Sidra Naz, Carolina Colli Cruz, Sharada Wali, Krishnavathana Varatharajalu, Pablo C Okhuysen, Nancy N Vuong, Yinghong Wang","doi":"10.20524/aog.2025.0994","DOIUrl":"10.20524/aog.2025.0994","url":null,"abstract":"<p><strong>Background: </strong>Several clinical factors increase the susceptibility of cancer patients to <i>Clostridioides difficile</i> infection (CDI), often resulting in lower CDI treatment response rates and higher rates of recurrent CDI (rCDI). Bezlotoxumab, a monoclonal antibody targeting and neutralizing <i>C. difficile</i> toxin B, demonstrates a significant reduction in rCDI rates compared to standard of care alone in the general population. However, the effectiveness of bezlotoxumab in the cancer patient population requires further investigation. We assessed the incidence of rCDI within 90 days of bezlotoxumab treatment in patients with cancer.</p><p><strong>Methods: </strong>This was a single-center retrospective cohort study conducted at a tertiary care cancer center, including patients who received bezlotoxumab with standard-of-care antibiotics for CDI or rCDI between March 2016 and January 2023. Descriptive analyses were conducted.</p><p><strong>Results: </strong>A total of 177 patients with cancer who received bezlotoxumab were included. Most (76.8%) experienced <2 CDI episodes, whereas 23.2% experienced ≥2 episodes. Bezlotoxumab was administered a median of 10 days (interquartile range [IQR] 5-12.5) after symptom onset, and fidaxomicin was the most frequently used concurrent antibiotic (41.2%). Eleven patients (6.2%) underwent fecal microbiota transplantation before or after bezlotoxumab treatment. The overall 90-day rCDI recurrence rate was 6.2% (11 patients), with a median time to recurrence of 50 days (IQR 25-58).</p><p><strong>Conclusions: </strong>Bezlotoxumab demonstrated high efficacy in reducing rCDI within a 90-day period after administration, compared to rates in the non-cancer population. The findings suggest that administration of bezlotoxumab for rCDI prevention should be considered, given the improvement in the outcome of this high-risk group.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 5","pages":"519-525"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in the burden of gastrointestinal diseases: a comprehensive analysis of data from randomized clinical trials from 2000-2023.","authors":"Wissam Ghusn, Khushboo Gala, Rudy Mrad, Marita Salame, Serena J Rahme, Hector Reyes Santiago, Arpan Mohanty, Laura Chiu, Jana G Hashash, Victor Chedid","doi":"10.20524/aog.2025.0997","DOIUrl":"10.20524/aog.2025.0997","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal (GI) conditions, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), metabolic dysfunction-associated steatotic liver disease (MASLD), and gastroesophageal reflux disease (GERD) are major contributors to morbidity and the healthcare burden. Randomized controlled trials (RCTs) are essential for advancing evidence-based medicine, but disparities in participant recruitment often limit the generalizability of trial findings. This study aimed to investigate demographic disparities in GI-related clinical trials, comparing trial populations to real-world data in order to identify gaps in recruitment.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted using data from United States RCTs from 2000-2023 that focused on major GI conditions: IBD, IBS, MASLD, and GERD. Demographic variables, including age, sex, gender, race and ethnicity, were collected and compared to real-world data from national health surveys. Descriptive statistics summarized the demographic distribution within the trials and highlighted disparities.</p><p><strong>Results: </strong>The analysis revealed significant disparities in recruitment across multiple GI conditions. Despite the growing burden of chronic diseases in older populations, older adults were underrepresented across trials, as a majority of participants were aged between 18 and 65 years. Sex and gender disparities were also observed, with underrepresentation of females in IBD trials and overrepresentation in IBS and MASLD trials, and no representation of gender diverse individuals. White participants were mostly overrepresented, while Black, Asian, and Hispanic individuals were underrepresented in several trials.</p><p><strong>Conclusion: </strong>This study underscores the need for more inclusive recruitment strategies in clinical trials to ensure diverse representation across age, sex, gender, and race.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 5","pages":"488-496"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-onset colorectal cancer in patients younger than 50 years: a systematic review of the literature.","authors":"Ilektra D Kyrochristou, Georgios D Lianos, Gerasimia D Kyrochristou, Vaia Georvasili, Vasileios Tatsis, Michail Mitsis, Dimitrios Schizas, Konstantinos Vlachos","doi":"10.20524/aog.2025.0977","DOIUrl":"10.20524/aog.2025.0977","url":null,"abstract":"<p><p>Early-onset colorectal cancer (EO-CRC) refers to CRC diagnosed before the age of 50. Its incidence has risen in recent years, turning researchers' attention to its oncologic behavior and potentially modifiable risk factors. In this review, PubMed/MEDLINE database was searched for all original research articles concerning EO-CRC. The inclusion criteria were CRC patients under 50, without a known predisposing factor for malignancy or an inherited CRC syndrome, presenting oncological characteristics and outcomes. All studies were assessed for bias, based on the ROBINS-E 2022 tool, and were synthesized in a qualitative analysis. Twenty-nine articles, reporting on 64,376 EO-CRC patients, were included in the qualitative synthesis. Results were classified into 3 categories: a) demographics; b) histopathologic characteristics; and c) treatment outcomes. Of these publications, 21 studies agreed that rectum (45%) and left-sided (47.1%) cancers are most common in younger patients, and 5 indicated that the highest prevalence of CRC concerns the 40-49 years age group. Seventeen of 29 studies reported a higher stage (III and IV) on diagnosis, with lymphovascular and perineural invasion. Our review has some limitations: as it was based on a single database, not all studies provided information on the variables; and patients were not categorized in all studies in the same age groups, although all were under 50 years. As EO-CRC is on the rise, the need for closer monitoring and possibly earlier screening becomes apparent. Further research should focus on finding novel screening biomarkers and modifiable risk factors that would decrease mortality and improve patient outcomes.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 4","pages":"364-379"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of early- versus late-onset esophageal adenocarcinoma: insights from the National Inpatient Sample 2016-2020.","authors":"Sana Rabeeah, Ahmad Mahdi, Vikash Kumar, Jayalekshmi Jayakumar, Bisher Sawaf, Shahem Abbarh, Ali Wakil, Hasan Al-Obaidi, Ahmed El Rahyel, Muhammed Elhadi, Yaseen Alastal","doi":"10.20524/aog.2025.0976","DOIUrl":"10.20524/aog.2025.0976","url":null,"abstract":"<p><strong>Background: </strong>The incidence of early-onset esophageal adenocarcinoma (EAC) in adults aged <50 years is rising, yet remains under-investigated. This study compared demographic, clinical and socioeconomic predictors of early- vs. late-onset EAC using national hospitalization data.</p><p><strong>Methods: </strong>We analyzed adult patients diagnosed with EAC from the National Inpatient Sample (2016-2020). Cases were stratified into early-onset (age <50 years) and late-onset (≥50 years), and further categorized by tumor location (upper, middle, lower esophagus). ICD-10-CM codes were used to identify diagnoses. Demographics, comorbidities and socioeconomic variables were compared using Rao-Scott chi-square tests.</p><p><strong>Results: </strong>Among 105,228 EAC admissions, early-onset cases comprised 5.89%. Lower esophagus involvement was most common (74.6%). Compared to late-onset patients, early-onset cases had a lower proportion of Caucasians (71.5% vs. 79.8%, P<0.001) and higher proportions of Black (13.9% vs. 9.6%) and Hispanic individuals (7.0% vs. 5.4%). Smoking (25.1% vs. 17.9%), obesity (11.4% vs. 8.4%), and drug use (28.9% vs. 19.7%) were more prevalent in early-onset patients (P<0.001). In contrast, late-onset patients had higher rates of hypertension (47.1% vs. 26.7%), diabetes, chronic obstructive pulmonary disease and gastroesophageal reflex disease (P<0.001). Early-onset patients were less likely to be insured with Medicare (6.8% vs. 57.9%), and more likely with Medicaid (35.0% vs. 10.6%) or to be self-payers (3.9% vs. 1.8%).</p><p><strong>Conclusions: </strong>Early-onset EAC presents with distinct racial, socioeconomic and clinical profiles compared to late-onset disease. These findings underscore the need for tailored screening strategies and further research to address disparities and risk factors in younger populations.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 4","pages":"392-400"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients with cystic fibrosis do not have an increased risk of adverse events after endoscopic retrograde cholangiopancreatography: a propensity-matched analysis.","authors":"Mahmoud Y Madi, Saqr Alsakarneh, Yassine Kilani, Ryan Plunkett, Razan Aburumman, Farah Heis, Christopher Nguyen, Christine Hachem, Wissam Kiwan","doi":"10.20524/aog.2025.0983","DOIUrl":"10.20524/aog.2025.0983","url":null,"abstract":"<p><strong>Background: </strong>Cystic fibrosis (CF) is a common life-limiting genetic disease often associated with hepatobiliary complications. Endoscopic retrograde cholangiopancreatography (ERCP), though valuable, carries procedural risks. We assessed the safety of ERCP in CF patients using real-world data.</p><p><strong>Methods: </strong>A retrospective cohort study using the TriNetX database (2010-2024) identified adults (≥18 years) with CF who underwent ERCP. Propensity-score matching adjusted for confounders, including age, sex, race, and hospitalization history. The primary outcome was post-ERCP pancreatitis (PEP); secondary outcomes included bleeding and infection. Subgroup analysis evaluated outcomes in patients with choledocholithiasis.</p><p><strong>Results: </strong>Among 534 matched CF patients (mean age 44.6 years; 48.3% female), rates of PEP (8.3% vs. 4.9%, adjusted odds ratio [aOR] 1.76, 95% confidence interval [CI] 0.937-3.315; P=0.075), bleeding (3.1% vs. 2.1%, aOR 1.52, 95%CI 0.674-3.409; P=0.31), and infection (3.7% vs. 2.4%, aOR 1.55, 95%CI 0.638-3.785; P=0.33) were not significantly different compared to non-CF controls. Subgroup analysis of choledocholithiasis patients similarly showed no significant differences.</p><p><strong>Conclusions: </strong>ERCP in CF patients demonstrated comparable adverse event rates to non-CF controls. These findings support the procedural safety of ERCP in this population, though further prospective studies are needed to validate these results and clarify risk by indication.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 4","pages":"446-452"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased capture of post-endoscopic retrograde cholangiopancreatography adverse events by delayed (day 7) follow-up calls: a prospective comparison of physician- and nurse-initiated calls.","authors":"Monique T Barakat, Subhas Banerjee","doi":"10.20524/aog.2025.0970","DOIUrl":"10.20524/aog.2025.0970","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic retrograde cholangiopancreatography (ERCP) is a high-risk endoscopic procedure. We recently found that physician-initiated post-ERCP follow-up calls on day 7 post-ERCP increased adverse event capture. Subsequently, we prospectively evaluated the utility of nurse-initiated follow-up calls, comparing these with physician-initiated calls to assess the impact of transitioning this responsibility to a nurse.</p><p><strong>Methods: </strong>This prospective study was conducted on consecutive patients undergoing ERCP at our academic tertiary care medical center. Patients received phone calls on days 1 and 7 post-ERCP, from either an endoscopist or a nurse coordinator, using a standardized script to assess delayed complications (pancreatitis, non-pancreatitis abdominal pain, bleeding, infection, perforation), and unplanned health encounters.</p><p><strong>Results: </strong>A total of 448 ERCP patients (239 physician calls, 209 nursing calls) were included. Physician calls were more successful than nursing calls in reaching patients on both day 1 (96% vs. 74%, P<0.001) and day 7 (91% vs. 63%, P<0.001). Nursing calls were significantly longer than physician calls on both days. A higher adverse event capture rate by physician calls compared to nursing calls was evident on day 1 (3.5% vs. 2.4%, P=0.04) and day 7 (10.6% vs. 6.3%, P=0.004). Physician follow-up calls on day 7 resulted in substantially more patients triaged to the Emergency Department, primary care and oncology clinics (P<0.001).</p><p><strong>Conclusions: </strong>Physician calls were significantly more effective than nurse calls in reaching patients, capturing adverse events, and triaging patients to appropriate care. These data support the value of physician-initiated calls, at least following the most complex procedures.</p>","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 4","pages":"440-445"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Replication and extension of a meta-analysis of antidepressants for irritable bowel syndrome: a comparison of odds ratios and risk ratios using artificial intelligence-powered tools.","authors":"Lefteris Teperikidis, Christos Mademlis, Georgios Hatzinakos, Nikolaos Lazaridis","doi":"10.20524/aog.2025.0975","DOIUrl":"10.20524/aog.2025.0975","url":null,"abstract":"","PeriodicalId":7978,"journal":{"name":"Annals of Gastroenterology","volume":"38 4","pages":"462-463"},"PeriodicalIF":2.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}